TaskUs India Awarded as One of Asia's Most Inspiring Workplaces in 2025
TaskUs (Nasdaq: TASK), a global leader in outsourced digital services and next-generation customer experience, has been named one of Asia's Most Inspiring Workplaces for 2025 by the Inspiring Workplaces Group (IWG). The recognition highlights the organization's unwavering focus on innovation, inclusion and an employee-first mindset, evaluated across six pillars: culture and purpose, leadership, well-being, inclusion, employee voice and overall experience.
TaskUs India Awarded as One of Asias Most Inspiring Workplaces in 2025
'We're deeply honored to be recognized on this prestigious platform,' said Sapna Bhambani, Senior Vice President of Operations and Country Leader, TaskUs India. 'This award reflects the intentional culture we've built- one that champions psychological safety, celebrates individuality and supports personal and professional growth at every step. Our people power our performance and this culture drives our success.'
With a workforce of over 12,000, the India operations have distinguished themselves through a frontline-first philosophy and a comprehensive set of employee-centric initiatives. These include inclusive medical coverage, enhanced leave policies, robust career development programs and a strong focus on mental wellness. The company also runs signature programs such as Hope Beyond Life, which provides continued support to families of deceased employees including healthcare, scholarships and employment assistance underscoring its long-term commitment to care.
Workspaces in Indore, Gurugram and Mohali are thoughtfully designed to support well-being and inclusivity, with on-site gyms, daycare centers and gender-neutral restrooms, enabling work-life integration and accessibility.
The Asia recognition for India adds to a growing list of global accolades the company has earned in 2025, with operations in the Philippines also recognized, Colombia honored in Latin America and Greece being featured among the top workplaces in Europe – underscoring the brand's consistent commitment to people-first practices across regions worldwide.
TaskUs India is also a certified Great Place To Work for both 2023 and 2025, highlighting its leadership in shaping the future of work.
About TaskUs
TaskUs is a leading provider of outsourced digital services and next-generation customer experience for the world's most innovative companies. Known for its people-first culture and operational excellence, TaskUs enables clients to protect, scale, and elevate their brands. As of March 31, 2025, TaskUs had a global workforce of approximately 61,400 teammates across 28 locations in 12 countries, including India, the United States, and the Philippines. The company serves high-growth sectors such as social media, e-commerce, fintech, gaming, streaming, healthcare, and more.
To learn more, visit www.taskus.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
US stocks open near record as Micron results boost chip stocks
Wall Street 's S&P 500 and Nasdaq indexes opened near a record high on Thursday. Robust earnings from memory-chip maker Micron fueled optimism around artificial intelligence while investors assessed a slew of economic data. The Dow Jones Industrial Average rose 101.6 points, or 0.24%, at the open to 43,084.07. The S&P 500 rose 19.9 points, or 0.33%, at the open to 6,112.09, while the Nasdaq Composite rose 88.6 points, or 0.44%, to 20,062.187 at the opening bell. ETMarkets WhatsApp channel )
Time of India
2 hours ago
- Time of India
Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune's stock (NASDAQ: ALT) plunged roughly 60–64% in pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug, pemvidutide , for metabolic dysfunction-associated steatohepatitis (MASH). The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease area. What is the current stock price of Altimmune? As of June 26, 2025 , Altimmune is trading at $7.71 per share . This price represents a significant pullback from its recent highs, though it remains above its 52-week low. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo Current price: $7.71 52-week high: $11.16 52-week low: $3.55 Market cap: Estimated between $558 million to $625 million Also Read: US stock futures rise: Dow, S&P 500, and Nasdaq edge higher as Nvidia, BlackBerry, and QuantumScape rally Did pemvidutide meet its primary endpoint? Yes. The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks: Live Events 59.1% of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH space. Also Read: Intel layoffs 2025: Design engineers, software architects lose jobs - these key divisions are next What about weight loss and secondary benefits? Altimmune also highlighted significant weight loss among trial participants: 5.0% weight loss at 1.2 mg 6.2% at 1.8 mg , compared to 1.0% in placebo This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer interest. Why did the stock crash despite positive results? The issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this area. Are analysts still bullish on Altimmune? Yes, despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds a "Strong Buy" rating from analysts. That suggests potential upside of nearly 190% from the current price level, assuming pemvidutide regains investor confidence in later trials. What are the short-term stock trends for ALT? Technically, ALT has been highly volatile and is currently trading in the mid-range of its 52-week band . Short-term charts show neutral-to-bearish signals , with some analysts recommending caution until the stock finds support or stabilizes. What is MASH treatment? MASH, short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. What's next for Altimmune and pemvidutide? Altimmune will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under consideration. FAQs: What caused Altimmune stock to crash after the MASH trial? The stock crashed after its MASH drug failed to show strong results in improving liver fibrosis. Is Altimmune still moving forward with pemvidutide? Yes, the company plans to meet the FDA and may start a Phase 3 trial.
Economic Times
3 hours ago
- Economic Times
US stock futures rise: Dow, S&P 500, and Nasdaq edge higher as Nvidia, BlackBerry, and QuantumScape rally
US Stock futures ticked higher early Thursday, with the S&P 500 now just shy of its all-time high, gaining 0.3% in pre-market trading. The Nasdaq 100 futures rose 0.4%, while Dow Jones futures added 126 points. This rally follows a 22% rebound since April's low, driven by easing tariff fears and calming geopolitical tensions. President Donald Trump's ceasefire deal between Israel and Iran and focus on economic policies like the 'One Big Beautiful Bill Act' are in the spotlight. Investors now await jobless claims data and major earnings from Walgreens and Nike. Can the rally hold? Here's everything to watch. US Stock futures rose early Thursday as the S&P 500 nears its record high. With easing trade tensions, Trump's economic policies, and key earnings from Walgreens and Nike ahead, markets look hopeful. Get the full picture of today's market action. Tired of too many ads? Remove Ads Dow Jones futures are up 109 points , signaling a positive open. are up , signaling a positive open. S&P 500 futures are higher by 20.5 points , pointing to more record-chasing. are higher by , pointing to more record-chasing. Nasdaq-100 futures gained 109 points, fueled by fresh momentum in tech stocks. U.S. Stock Market Futures Overview Pre-market futures are up around 0.31–0.37% , trading near all‑time highs—about 22% higher since April lows , trading near all‑time highs—about E-mini S&P 500 futures are currently around 6,169.75, a rise of ~0.01% in the past 24 hours Tired of too many ads? Remove Ads E-mini Nasdaq‑100 futures have gained approximately 0.44%, now trading in the 22,560–22,570 range Dow futures are up by about 0.21–0.29% in pre-market activity Which major earnings are on the radar today? Walgreens is set to report before the bell, giving a glimpse into the health of the retail pharmacy sector. Nike will announce its results after market close, with investors eager to see how the brand is handling changing consumer spending trends. Which stocks are moving the most today? Top gainers: Nvidia (NVDA) jumped 4.3% , hitting yet another all-time high after analysts boosted their price targets amid soaring AI demand. jumped , hitting yet another all-time high after analysts boosted their price targets amid soaring AI demand. QuantumScape (QS) soared 31% following positive developments in its battery technology, reviving EV excitement. soared following positive developments in its battery technology, reviving EV excitement. BlackBerry (BB) rallied 13% after beating earnings estimates and raising its guidance. rallied after beating earnings estimates and raising its guidance. AeroVironment (AVAV) surged 22% , driven by strong revenue and defense-sector optimism. surged , driven by strong revenue and defense-sector optimism. Yum! Brands (YUM) got a nice bump after receiving a key analyst upgrade. Stocks under pressure: Paychex (PAYX) tumbled nearly 10% after missing revenue forecasts and issuing cautious commentary. tumbled nearly after missing revenue forecasts and issuing cautious commentary. FedEx (FDX) dropped around 4% — despite beating earnings, the company's weak outlook spooked investors. dropped around — despite beating earnings, the company's weak outlook spooked investors. General Mills (GIS) fell over 5% as consumer demand appeared soft despite an earnings beat. fell over as consumer demand appeared soft despite an earnings beat. Tesla (TSLA) slid nearly 4%, pressured by declining EV sales in Europe and ongoing price cut concerns. What are the key ETFs doing right now? SPDR S&P 500 ETF (SPY) is trading around $607.12 , up slightly in pre-market action. is trading around , up slightly in pre-market action. Invesco QQQ Trust (QQQ), which tracks the Nasdaq-100, is sitting near $541.16, reflecting strong demand for tech. Why is the S&P 500 rallying again and how close is it to the record? Are tensions in the Middle East easing and what's Trump's stance? Tired of too many ads? Remove Ads What do Wall Street experts say about the stock market momentum? What economic data are investors waiting for today? Can stock futures lead to a new S&P 500 record? FAQs: US Stock futures nudged upward early Thursday as Wall Street eyes another potential record for the S&P 500, which is now less than 1% below its all-time high. After a quiet session on Wednesday, where the index closed nearly flat, investors are watching closely as market momentum builds. As of the early morning hours, S&P 500 futures rose 0.3%, Nasdaq 100 futures climbed 0.4%, and Dow Jones Industrial Average futures added 126 points or 0.2%.Markets have gained steadily in recent months, with the S&P 500 up more than 22% since its April low, which was triggered by tariff fears at the time. While those trade worries have cooled, some experts remain cautious about how long the current rally can uptick comes as markets digest cooling inflation data and encouraging signs from Federal Reserve Chair Jerome Powell, who hinted at flexibility in upcoming policy season continues, and two big names are in the spotlight today:Strong earnings could help sustain the current rally, especially as the market tests new S&P 500 has been riding a steady upward wave, now within less than 1% of its record set in February. The rally has been fueled by easing geopolitical fears, improved investor sentiment, and better-than-expected corporate earnings. The benchmark index has recovered more than 22% from its April closing low when fears over U.S. tariffs spooked return of market optimism comes as the One Big Beautiful Bill Act, championed by President Donald Trump, continues to stir debate over fiscal policy and its long-term economic key reason behind the recent calm in the markets is the perceived de-escalation in the Middle East. President Trump confirmed on Tuesday that a ceasefire between Israel and Iran is now in place, even though he expressed frustration, saying he's 'not happy' with how both sides have handled the situation. Despite these concerns, the ceasefire seems to be holding for diplomatic efforts continue. A U.S.-Iran meeting is scheduled for next week, which could further stabilize global markets if progress is everyone is convinced that this bullish trend will last. Komal Sri-Kumar, president of Sri-Kumar Global Strategies, told CNBC's Power Lunch on Wednesday, 'The various macro factors that I'm looking at seem to suggest that there's no way this situation can continue.'ongoing global tensions, Trump's tariffs, and the potential fiscal consequences of new legislation. There's growing concern that fiscal deficits might widen under the current administration's economic plans, adding pressure on the long-term are closely watching weekly jobless claims data, set to be released at 8:30 a.m. ET Thursday. This report offers a key look at how the labor market is performing — a crucial factor in shaping Fed policy and investor expectations. A stronger-than-expected number could boost confidence, while a weak showing might add pressure on stock futures ticking higher, all eyes are on whether the S&P 500 can break through its February peak. While recent gains are encouraging, concerns about global politics, U.S. fiscal health, and corporate performance still should remain alert as key earnings and data releases continue to shape the market's next move. Whether this rally can hold or falter will depend on how the economy and policy decisions play out in the coming weeks — and how much risk appetite investors still have futures are up due to easing global tensions and upcoming economic S&P 500 is now within 1% of its all-time peak.
